Ireland - English - HPRA (Health Products Regulatory Authority)

aurum pharmaceutical limited - magnesium sulphate heptahydrate - solution for injection and concentrate for infusion - 50 percent weight/volume - electrolyte solutions; magnesium sulfate

Ireland - English - HPRA (Health Products Regulatory Authority)

curium netherlands b.v. - sodium iodide (131 i) - capsule, hard - 37-7400 megabecquerel(s) - iodine (131i) compounds; sodium iodide (131i)

Australia - English - Department of Health (Therapeutic Goods Administration)

herbs of gold pty ltd - magnesium amino acid chelate, quantity: 750 mg (equivalent: magnesium, qty 150 mg); magnesium orotate dihydrate, quantity: 78.1 mg (equivalent: magnesium, qty 5 mg); magnesium glycinate, quantity: 106.4 mg (equivalent: magnesium, qty 15 mg); magnesium citrate, quantity: 309.4 mg (equivalent: magnesium, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; crospovidone; colloidal anhydrous silica; macrogol 8000; citric acid; titanium dioxide; carnauba wax; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; magnesium stearate; povidone; citric acid dihydrate - maintain/support energy production ; maintain/support general health and wellbeing ; maintain/support bone health ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; decrease/reduce/relieve muscle cramps ; helps reduce occurrence of muscle cramp ; maintain/support healthy muscle contraction function ; maintain/support muscle health ; maintain/support muscle function ; aid/assist/helps glucose/sugar/carbohydrate metabolism ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; support healthy stress response in the body ; maintain/support nervous system health ; maintain/support nervous system function ; decrease/reduce/relieve menstrual spasms/cramps ; decrease/reduce/relieve menstruation pain/dysmenorrhoea ; decrease/reduce/relieve symptoms of premenstrual tension ; maintain/support healthy pregnancy

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Canada - English - Health Canada

pfizer canada ulc - calcium chloride - solution - 100mg - calcium chloride 100mg - replacement preparations

Canada - English - Health Canada

fresenius kabi canada ltd - calcium gluconate - solution - 100mg - calcium gluconate 100mg - replacement preparations

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contains calcium acetate.  animal reproduction studies have not been conducted with calcium acetate capsules, and there are no adequate and well controlled studies of calcium acetate capsules use in pregnant women.  patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] .  maintenance of normal serum calcium levels is important for maternal and fetal well being.  hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism.  calcium acetate capsules treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium a

United States - English - NLM (National Library of Medicine)

pharmin usa, llc - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate tablet is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd).

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see ]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. warnings and precautions (5.1) the effects of calcium acetate

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. a